

14th

Canadian Kidney Cancer Forum

February 27-March 1, 2025

Sheraton Gateway Hotel, Toronto, ON

KCRNC

KIDNEY CANCER RESEARCH
NETWORK OF CANADA

RRCRC

RÉSEAU DE RECHERCHE SUR LE
CANCER DU REIN DU CANADA



PROGRAM




#CKCF25



Meeting Chair

Tony Finelli

Professor of Surgery and Chair of Urology, University of Toronto
Head, Division of Urology, University Health Network (UHN)
Anna-Liisa Farquharson Chair in Kidney Cancer Research



Meeting co-Chairs

Bimal Bhindi

Clinical Associate Professor, Cumming School of Medicine,
Division of Urology, Department of Surgery
University of Calgary



Dominick Bossé

Assistant Professor, Division of Medical Oncology
University of Ottawa

Invited Speakers



Mark Ball

Associate Research Physician, National Cancer Institute
Associate Program Director, Urologic Oncology Fellowship
Program




Jaclyn Beca

Director of Pharmacoeconomics and RWE, Morse Consulting



Naomi Haas

Director, Prostate and Kidney Cancer, Penn Medicine
Professor, Medicine (Hematology-Oncology),
Hospital of the University of Pennsylvania



Wenxin Xu

Assistant Professor, Medicine, Harvard Medical School
Physician, Medical Oncology, Dana-Farber Cancer Institute

Canadian Faculty



Bob Bick

Director, Kidney Cancer Canada



Jeffrey Graham

Scientist, Clinical Research, CancerCare Manitoba
Research Institute
Medical Oncologist, Department of Oncology and Hematology,
CancerCare Manitoba
Assistant Professor, Department of Internal Medicine,
University of Manitoba



Michael Jewett

International Kidney Cancer Coalition (IKCC)



Raymond Kim

Medical geneticist, Princess Margaret Hospital, Toronto, ON



Christian Kollmannsberger

Medical Oncologist, BC Cancer
Head, Department of Medical Oncology, BC Cancer
Chair, British Columbia Genitourinary Tumour Group



Aly-Khan Lalani

Associate Professor, Department of Oncology,
McMaster University
Vice Chair, Medical Oncology,
CUA Education Office



Frédéric Pouliot

Associate Professor, Department of Surgery
Faculty of Medicine, CHU de Québec

14th

Canadian Kidney Cancer Forum

THURSDAY, FEBRUARY 27, 2025

- 17:00 - 18:30 Registration opens / badge pickup
18:45 - 19:25 Networking Dinner in DeGaulle
19:30 Session 1 in Gateway Ballroom

SESSION I: INTRODUCTION

(19:30 - 20:55)

Moderators: Bimal Bhindi, Dominick Bossé

Meeting room: Gateway Ballroom

- 19:30 - 19:35 **Welcome**
Tony Finelli
- 19:35 - 19:45 **Overview of program**
Bimal Bhindi, Dominick Bossé
- 19:45 - 20:10 **Avenues for future research in neoadjuvant therapies for RCC**
Naomi Haas
- 20:10 - 20:20 Discussion & Q/A
- 20:20 - 20:45 **The future of anti-HIF alpha and novel targets in RCC**
Wenxin Xu
- 20:45 - 20:55 Discussion & Q/A
- 21:00 - 23:00 **Networking mix and mingle:** Trudeau room

FRIDAY, FEBRUARY 28, 2025

- 07:00 - 08:00 **Networking breakfast with exhibitors**
Gateway Ballroom/DeGaulle

SESSION 2: LOCALIZED RCC DIAGNOSTICS AND MANAGEMENT

(08:15 - 09:15)

Moderators: Ali Fawaz, Melissa Huynh

Meeting room: Gateway Ballroom

- 08:15 - 08:35 **Opportunities for Canadian research on novel imaging and theranostics in RCC**
Frédéric Pouliot
- 08:35 - 08:45 Discussion & Q/A
- 08:45 - 09:05 **Approaches to optimizing outcomes in kidney cancer surgery**
Mark Ball
- 09:05 - 09:15 Discussion & Q/A
- 09:15 - 09:30 **Networking break with exhibitors and poster viewing**
Gateway Ballroom/DeGaulle

February 27 to March 1, 2025 • Sheraton Gateway Hotel, Toronto, ON

14th

Canadian Kidney Cancer Forum

SESSION 3: ADJUVANT RCC

(09:30 - 10:40)

Moderator: Rodney Breau

DEBATE

- 09:30 - 09:40 **All patients with moderate-to high-risk RCC should be treated with adjuvant pembrolizumab**
Naomi Haas
- 09:40 - 09:50 **Adjuvant pembrolizumab should not be offered routinely to moderate-to high-risk RCC patients**
Christian Kollmannsberger
- 09:50 - 10:00 Discussion & Q/A
- 10:00 - 10:15 **Novel biomarkers to predict recurrence**
Wenxin Xu
- 10:15 - 10:40 **PANEL DISCUSSION:**
Moderator: Rodney Breau
Panel: Naomi Haas, Christian Kollmannsberger, Wenxin Xu

SESSION 4: GENETIC SYNDROMES IN RCC

(10:40 - 11:55)

Moderators: Joel Gingerich, Stephen Pautler

- 10:40 - 10:55 **Kidney cancer genetics, simplified**
Raymond Kim
- 10:55 - 11:25 **Contemporary management of patients diagnosed with genetic renal tumor syndromes and future direction**
Mark Ball
- 11:25 - 11:35 Discussion & Q/A
- 11:35 - 11:50 **CUA presentation**
Aly-Khan Lalani
- 11:50 **Commemorative annual CKCF photo**
- 12:00 - 13:00 **Networking lunch with exhibitors and poster viewing**
Gateway Ballroom/DeGaulle

SESSION 5: RESEARCH BREAKOUT SESSIONS

(13:00 - 15:00)

- 13:00 - 13:05 **Therapeutics: Highlights from 2024 meeting**
Jeffrey Graham
- 13:05 - 13:10 **Survivorship: Highlights from 2024 meeting**
Tran Truong

February 27 to March 1, 2025 • Sheraton Gateway Hotel, Toronto, ON

14th

Canadian Kidney Cancer Forum

- 13:10 - 13:15 **Diagnostics: Highlights from 2024 meeting**
Aly-Khan Lalani
- 13:15 - 14:15 **BREAKOUT: Prospective, multicentre study: What are the next steps in Canada?**
Moderators: Sebastien Hotte, Luke Lavallée
Invited faculty: Mark Ball
Room: Gateway Ballroom
- BREAKOUT: Real-world database studies: What questions can our current resources answer?**
Moderators: Daniel Heng, Alexis Rompré-Brodeur
Invited faculty: Naomi Haas
Room: O'Hare
- BREAKOUT: Translational Canadian collaborative projects: What initiatives should we focus on?**
Moderators: Keith Lawson, Yasser Riazalhosseini
Invited faculty: Wenxin Xu
Room: LaGuardia
- 14:15 - 15:00 **Breakout sessions presentation to group**
(15 minutes per group)
- 15:30 **Departure for group activity**
- 19:30 - 21:00 **CKCF networking recognition dinner**
Gateway Ballroom

SATURDAY, MARCH 1, 2025

- 07:00 - 08:00 **Networking breakfast with exhibitors**
Gateway Ballroom/DeGaulle

SESSION 6: DRUG FUNDING, ACCESS, AND ADVOCACY

(08:00 - 09:05)

Moderators: Marion Cooper, Simon Tanguay
Meeting Room: Gateway Ballroom

- 08:00 - 08:20 **Bridging the gap to access: Navigating evolving trends in oncology drug reimbursement**
Jaclyn Beca
- 08:20 - 08:30 **Drug approval process in Canada and how clinicians can get involved**
Aly-Khan Lalani
- 08:30 - 08:40 **Impact of stakeholder advocacy**
Bob Bick

February 27 to March 1, 2025 • Sheraton Gateway Hotel, Toronto, ON

14th

Canadian Kidney Cancer Forum

08:40 - 08:50 **Improving cancer care outcomes with patient engagement**
Michael Jewett

08:50 - 09:05 Discussion

SESSION 7: RESEARCH UPDATE AND GRANTS

(09:05 - 11:15)

Moderators: Rahul Bansal, Ricardo Fernandes

09:05 - 10:05 **The Anil Kapoor Kidney Cancer Research Grant (CUASF/KCRNC/KCC)**

Grant presentation #1 (12 minutes plus 8 minutes Q/A)
Selecting Patients for Immunotherapy in Renal Cell Carcinoma Employing Artificial Intelligence (SPIRE-AI)
Changsu Larry Park, University Health Network

Grant presentation #2 (12 minutes plus 8 minutes Q/A)
Targeting ccRCC intrinsic immune evasion pathways to improve CAR-T cell therapy
Keith A. Lawson, Princess Margaret Cancer Centre

Grant presentation #3 (12 minutes plus 8 minutes Q/A)
Using Nanopore Technology To Develop Rapid, Real-Time, Clinical Molecular Oncology Testing
Rola Saleeb, St. Michael's Hospital

10:05 - 10:20 **Clinical trials update**
Jeffrey Graham

10:20 - 10:40 **Networking break with exhibitors**
Gateway Ballroom/DeGaulle

10:40 - 10:50 **Update from past recipients (presented virtually): Targeting PRMT1 in clear cell renal cell carcinoma**
Joseph Walton

10:50 - 11:00 **Radiomics and renal mass histology prediction**
Teodora Boblea Todasca

11:00 - 11:15 **Poster winners in clinical or basic science research**
Presented by Tony Finelli
The Anil Kapoor Kidney Cancer Research Grant (CUASF/KCRNC/KCC) Winner
Presented by Marion Cooper, Kidney Cancer Canada

SESSION 8: CONSENSUS BUILDING

11:15 - 12:15 **Expert Report: Surveillance and management of RCC in patients with genetic predisposition syndromes**
Bimal Bhindi, Dominick Bossé

12:15 **Adjournment**

February 27 to March 1, 2025 • Sheraton Gateway Hotel, Toronto, ON

WE WOULD LIKE TO THANK OUR SPONSORS

PLATINUM



SILVER



BRONZE



This event has been reviewed and approved by the Canadian Urological Association (CUA) as a Section 1 Group Learning Event, as deemed by the Maintenance and Certification Program of the Royal College of Physicians and Surgeons, for a maximum of 11 hours.

Canadian **U**rological Association
The Voice of Urology in *Canada*
The Voice of *Urologic Oncology* in *Canada*



Association des **U**rologues du Canada
La voix de l'urologie au *Canada*
La voix de l'*uro-oncologie* au *Canada*

cua.org